Skip to main content

Posts tagged with "Alzheimer’s Disease"

  • Alzheimer's Disease

    TauRx Reports on Their Alzheimer’s Drug. Unfortunately.

    It’s been a while since we heard from TauRx, the company that’s been developing an unusual Alzheimer’s therapy targeting tau protein instead of amyloid. They released interesting Phase II data some time ago, but they’ve been improving their formulation and going into a larger, longer Phase III, which is what anyone working… Read More
  • Alzheimer's Disease

    Muscarinic Agonists Come Back Around

    Allergan, now that they’re not going to be Pfizer, has wasted no time signing a big deal with Heptares for Alzheimer’s. Heptares, as the receptor-centric people in the readership will know well, has been working on GPCR structure for some years now, and applying this knowledge to their own drug discovery efforts. They have what… Read More
  • Alzheimer's Disease

    Is Lilly’s Big Alzheimer’s Trial in Trouble?

    Eli Lilly has been testing their solanezumab antibody against Alzheimer’s for some years now. The first rounds of clinical trials were. . .inconclusive at best. Perhaps there was a bit of an effect in the mildest-affected patient cohort, perhaps not. The company went for it, though, starting a second Phase III in a more carefully selected p… Read More
  • Alzheimer's Disease

    Microbial Alzheimer’s: The Arguing Continues

    The Journal of Alzheimer’s Disease has published an editorial, signed by thirty-one researchers from institutions across several continents, calling on a re-evaluation of the disease’s origins: We are researchers and clinicians working on Alzheimer’s disease (AD) or related topics, and we write to express our concern that one particu… Read More
  • Alzheimer's Disease

    Unpleasant Alzheimer’s News

    Here are a couple of new developments in Alzheimer’s and dementia – nothing encouraging, unfortunately. A new paper in JAMA Internal Medicine, from a team that’s looked at multiyear patient records, suggests that there’s a dose-response relationship between use of strong anticholinergic drugs and later development of dementi… Read More
  • Alzheimer's Disease

    A Dietary Cause for a Neurodegenerative Disease

    This is an interesting paper in itself, and its potential implications are even more so. The authors, from the Institute for Ethnomedicine and the University of Miami, have been studying a neurodegenerative condition found among Chamorro villagers on the island of Guam. The disease (Guamanian amyotrophic lateral sclerosis/parkinsonism dementia comp… Read More
  • Alzheimer's Disease

    A Fungal Origin For Alzheimer’s?

    Here’s a potentially interesting paper that’s recently appeared, saying that numerous brain regions in Alzheimer’s patients appear to show signs of fungal infection, as opposed to control samples. The authors claim detection through antibodies, and to have isolated fungal DNA as well, identifying several species. The authors (from… Read More
  • Alzheimer's Disease

    Prions In the News (Unfortunately)

    Let’s talk about proteins for a few minutes – nasty, unfriendly proteins, of the sort that will ball up and crash out of solution the first chance they get. Anyone working in a protein purification lab will have encountered plenty of these, and will be familiar with the various tricks available to keep things in… Read More
  • Aging and Lifespan

    Young Blood, Revisited

    Here’s an update on the state of those studies that showed that infusing blood of younger animals into olders ones reversed some effects of again. Human studies are underway – small, but worth keeping an eye on – from a startup out of Stanford called Alkahest. Their website isn’t really even running yet, but maybe… Read More
  • Alzheimer's Disease

    On the FDA, Drug Approvals, and Not Knowing Enough

    It doesn’t seem to have generated many headlines, but the FDA recently released a report (PDF) on the pace of drug development. Titled “Targeted Drug Development: Why Are Many Diseases Lagging Behind”, it seems to be motivated, at least in part, by a desire to answer “Not Because of Us!” The agency goes into some deta… Read More